In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same? (Q37855152)

24 August 2017

1 reference

title

In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same? (English)

1 reference

24 August 2017

1 reference

1

Ana Espinel-Ingroff

1 reference

24 August 2017

Emilia Cantón

2

1 reference

24 August 2017

1 March 2011

1 reference

Infectious Diseases and Clinical Microbiology

24 August 2017

1 reference

24 August 2017

29 Suppl 2

1 reference

24 August 2017

3-9

1 reference

Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility

24 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

New antimicrobial agents approved by the US Food and Drug Administration in 2003 and new indications for previously approved agents

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

New antimicrobial agents approved by the U.S. Food and Drug Administration in 2004 and new indications for previously approved agents

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

New antimicrobial agents approved by the U.S. Food and Drug Administration in 2005 and new indications for previously approved agents

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Anidulafungin versus fluconazole for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Breakthrough invasive candidiasis in patients on micafungin

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Acquired resistance to echinocandins in Candida albicans: case report and review

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Novel FKS mutations associated with echinocandin resistance in Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Serum differentially alters the antifungal properties of echinocandin drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Effects of caspofungin against Candida guilliermondii and Candida parapsilosis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

Time-kill studies investigating the killing activity of caspofungin against Candida dubliniensis: comparing RPMI-1640 and antibiotic medium 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2811%2970002-7

7 January 2021

10.1016/S0213-005X(11)70002-7

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/eemxguailzhvpegah77lvksnl4

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_eemxguailzhvpegah77lvksnl4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/eemxguailzhvpegah77lvksnl4

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/eemxguailzhvpegah77lvksnl4

30 July 2022